Lineage switching is an additional mechanism of resistance to CD19-CAR T cell therapy, usually described as the transition from Acute Lymphocytic Leukemia (ALL) to Acute Myeloid Leukemia (AML) or myeloid sarcoma upon relapse [8,69]. Here, CD19 is linked to acute myeloid leukemia.